Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01468701 · ClinicalTrials.gov registry record
GLORIA-AF Registry Program - Second and Third Phases
A clinical trial of Stroke and Atrial Fibrillation, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 37,235
- Enrollment target
- 20
- Study locations
NCT01468701: Completed study of Stroke and Atrial Fibrillation, sponsored by Boehringer Ingelheim.
NCT01468701 is a study of Stroke and Atrial Fibrillation that has completed, run by Boehringer Ingelheim. The registered enrollment target is 37,235 participants, above the 11,934-participant average among 454 other Stroke trials with a reported enrollment target (212% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01468701, a study of Stroke and Atrial Fibrillation, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 37,235 participants
- Enrollment target
- 20
- Study locations
Study Summary
In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events. For administrative purposes the study is divided into two protocol numbers: 1160.129 for all non-EU (European Union) and non-EEA (European Economic Area) countries, and 1160.136 for EU and EEA countries. The total number of patients enrolled in both protocols is estimated to be 48,000 patients, and all these patients will be included in the data analysis for study 1160.129.
Primary Outcome
Incidence rate of composite outcome which includes events of Stroke, systemic embolism, myocardial infarction, life-threatening bleeding events and vascular death on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only. In case of multiple events for a patient, the first event was considered.
Conditions Studied
Study Locations (20)
California
- Diagnamics, Inc - Encinitas
- Allianz Medical and Research Center - Fountain Valley
- B&K Medical Research Center - Fresno
- American Clinical Trials - Hawaiian Gardens
- Scripps Clinic - La Jolla
- La Mesa Cardiac Center - La Mesa
- Los Alamitos Cardiovascular - Los Alamitos
- VA Greater Los Angeles Healthcare System - Los Angeles
Arkansas
- Sparks Regional Medical Center - Fort Smith
- Dr. Michael A. Frais, Cardiologist, P.A. - Hot Springs
- Cardiology and Medicine Clinic - Little Rock
- Donald W. Reynolds Institute on Aging - Little Rock
- Arkansas Cardiology, PA - Little Rock
Alabama
- University South Alabama Medical Center - Mobile
- Black Warrior Research - Northport
- Scottsboro Quick Care Clinic - Scottsboro
Arizona
- Phoenix Heart PLLC - Glendale
- Mercy Cinic Hot Springs Communities - Hot Springs
- Midwest Internal Medicine, PLLC - Lake Havasu City
Alaska
- Alaska Heart Institute - Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37,235 participants |
| Start Date | 2011-11-07 |
| Est. Completion | 2020-01-10 |
What the finished NCT01468701 record still lists
NCT01468701 is an observational study that tracks outcomes without assigning an intervention. Its 37,235 participants enrollment target places it among the larger protocols in the corpus, above the 11,934-participant average among 454 other Stroke trials with a reported enrollment target (212% higher).
The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 0 interventions.
NCT01468701 names 20 study sites across 5 states, led by California, Arkansas, Alabama.
Frequently Asked Questions
What is clinical trial NCT01468701 about?
NCT01468701 is a clinical study titled "GLORIA-AF Registry Program - Second and Third Phases". In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events. For administrative purposes the study is divided into two protocol numbers: 1160....
What is the current status of trial NCT01468701?
This trial is currently completed. The enrollment target is 37,235 participants. The study started on 2011-11-07. Estimated completion is 2020-01-10.
What conditions does trial NCT01468701 study?
This clinical trial studies the following conditions: Stroke, Atrial Fibrillation.
Who is sponsoring clinical trial NCT01468701?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01468701 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01468701's enrollment target sits among peer trials
37,235 5th of 454 higher than 450 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The SLEEPR Study: SLEep Effects on Post-stroke Rehabilitation
RECRUITING
-
Tracking a Tactile Signal Along the Nervous System
RECRUITING · NA
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Genetic and Environmental Risk Factors for Hemorrhagic Stroke
RECRUITING
-
Strategy Training for Individuals With Unilateral Neglect
RECRUITING · NA
-
Weight Loss and ExeRcise
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05796505 · 37,122 participants · NA
Addressing Vaccine Acceptance in Carceral Settings Through Community Engagement
- NCT07150923 · 36,503 participants · NA
Supraglottic Airway for Resuscitation Trial
- NCT03262259 · 36,000 participants · NA
Evaluation of Global Smart Drinking Goals Initiative
- NCT02225301 · 35,000 participants · NA
iLookOut for Child Abuse -Online Learning Module for Early Childcare Providers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI